首页> 外文期刊>Drug Design, Development and Therapy >Azelnidipine plus olmesartan versus amlodipine plus olmesartan on arterial stiffness and cardiac function in hypertensive patients: a randomized trial
【24h】

Azelnidipine plus olmesartan versus amlodipine plus olmesartan on arterial stiffness and cardiac function in hypertensive patients: a randomized trial

机译:阿兹尼地平加奥美沙坦与氨氯地平加奥美沙坦对高血压患者动脉僵硬和心功能的影响:一项随机试验

获取原文
       

摘要

Purpose: To compare the long-term effects of olmesartan combined with either azelnidipine or amlodipine on central blood pressure (CBP), left ventricular (LV) mass index (LVMI), LV diastolic function (e′ velocity, E/e′ ratio, E/A ratio) and arterial stiffness (brachial-ankle pulse wave velocity [baPWV] and augmentation index normalized for a heart rate of 75 bpm [AIx]).Patients and methods: Patients with systolic BP ≥140 mmHg and/or diastolic BP ≥ 90 mmHg received olmesartan monotherapy (20 mg/day) for 12 weeks. They were then randomly assigned to fixed-dose add-on therapy with azelnidipine (16 mg/day; n = 26) or amlodipine (5 mg/day; n = 26) for a further 2 years. CBP, LVMI, e′ velocity, E/e′ratio, E/A ratio, baPWV, and AIx were measured at baseline, 6 months, and 2 years.Results: Baseline characteristics of both groups were similar. The decrease in brachial BP over 2 years was similar in both groups. CBP, LVMI, E/e′ ratio, baPWV, and AIx decreased significantly, and the E/A ratio and e′ velocity increased significantly in both groups. The decreases in CBP (P < 0.001), AIx (P < 0.001), baPWV (P < 0.001), LVMI (P < 0.001), and E/e′ (P = 0.002) as well as the increase in E/A ratio (P = 0.03) over 2 years were significantly greater in the olmesartan/azelnidipine group than in the olmesartan/amlodipine group. Multivariate linear regression analyses showed that the changes in baPWV (β = 0.41, P < 0.001) and CBP (β = 0.47, P = 0.01) were independently associated with the change in LVMI, the change in baPWV (β = 0.25, P < 0.001) was independently associated with the change in E/e′ ratio, and the changes in baPWV (β = 0.21, P = 0.001) and AIx (β = 0.25, P = 0.03) were independently associated with the change in E/A ratio.Conclusion: Treatment with olmesartan/azelnidipine for 2 years resulted in greater improvements in CBP, LVMI, and LV diastolic function, and arterial stiffness compared with olmesartan/amlodipine. Improvements in LV diastolic function were associated with improvements in arterial stiffness.
机译:目的:为了比较奥美沙坦与阿兹地平或氨氯地平联合对中心血压(CBP),左心室(LV)质量指数(LVMI),左室舒张功能(e'速度,E / e'比, E / A比)和动脉僵硬度(以75 bpm的心率归一化的肱踝脉搏波速度[baPWV]和增强指数[AIx])。患者和方法:收缩压≥140 mmHg和/或舒张压的患者≥90 mmHg接受奥美沙坦单药治疗(20 mg /天),持续12周。然后将他们随机分配接受阿兹地平(16 mg /天; n = 26)或氨氯地平(5 mg /天; n = 26)的固定剂量追加治疗,持续2年。在基线,6个月和2年时测量CBP,LVMI,e'速度,E / e比,E / A比,baPWV和AIx。结果:两组的基线特征相似。两组的肱动脉血压在两年内的下降相似。两组的CBP,LVMI,E / e'比,baPWV和AIx均显着降低,E / A比和e'速度均显着提高。 CBP(P <0.001),AIx(P <0.001),baPWV(P <0.001),LVMI(P <0.001)和E / e'(P = 0.002)的降低以及E / A的增加与奥美沙坦/氨氯地平组相比,奥美沙坦/阿兹尼地平组在两年内的比率(P = 0.03)显着更大。多元线性回归分析显示baPWV(β= 0.41,P <0.001)和CBP(β= 0.47,P = 0.01)的变化与LVMI的变化独立相关,baPWV(β= 0.25,P < 0.001)与E / e'比的变化独立相关,而baPWV(β= 0.21,P = 0.001)和AIx(β= 0.25,P = 0.03)的变化独立于E / A的变化结论:与奥美沙坦/氨氯地平相比,用奥美沙坦/阿兹尼地平治疗2年可导致CBP,LVMI和LV舒张功能以及动脉僵硬度的改善更大。左室舒张功能的改善与动脉僵硬度的改善有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号